Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Retina ; 35(6): 1128-34, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25635575

ABSTRACT

PURPOSE: After the recent approval of ocriplasmin by the Food and Drug Administration, postmarketing safety concerns have been raised by the vitreoretinal community. The American Society of Retina Specialists Therapeutic Surveillance Committee was commissioned to monitor postmarketing drug-related and device-related adverse events. The purpose of this report is to analyze the postmarketing safety experience in the context of available premarketing safety data. METHODS: Periodic aggregate safety reports consisting of premarketing, or clinical trial, data (n = 999 injections) and postmarketing reports through July 16, 2013 (n = 4,387 injections), were retrospectively analyzed by the TSC. The aggregate data were analyzed to classify adverse events, and the postmarketing safety data for each event type were compared with the premarketing data. RESULTS: Eight categories of adverse events were identified. Acute reduction in visual acuity attributable to either worsening of macular pathology or development of subretinal fluid, electroretinogram changes, dyschromatopsia, retinal tears and detachments, lens subluxation or phacodonesis, impaired pupillary reflex, and retinal vessel findings were reported in both the premarketing and postmarketing experiences. Ellipsoid zone (inner segment/outer segment) findings were only reported in the postmarketing experience. Rates of postmarketing reports were lower than in the premarketing data. Adverse events were generally transient, and characteristics of these adverse events were generally similar between the premarketing and postmarketing experience. CONCLUSION: Postmarket analyses are limited by significant underreporting, and in the case of ocriplasmin as a first in-class drug, they may not have captured safety events that have only more recently been identified. Nonetheless, postmarket analyses can identify the scope of potential safety events based on real-world experiences. Ocriplasmin administration should be guided by an appropriate and informed risk-benefit discussion with the patient. Ongoing active postmarket surveillance by all practitioners will continue to be critical to better understand this safety profile.


Subject(s)
Drug-Related Side Effects and Adverse Reactions/etiology , Eye Diseases/drug therapy , Fibrinolysin/adverse effects , Fibrinolytic Agents/adverse effects , Peptide Fragments/adverse effects , Product Surveillance, Postmarketing , Retinal Diseases/drug therapy , Vitreous Body/drug effects , Clinical Trials as Topic , Color Vision Defects/chemically induced , Drug Evaluation, Preclinical , Electroretinography/drug effects , Fibrinolysin/therapeutic use , Fibrinolytic Agents/therapeutic use , Humans , Intravitreal Injections , Lens Subluxation/chemically induced , Peptide Fragments/therapeutic use , Photoreceptor Cells, Vertebrate/drug effects , Photoreceptor Cells, Vertebrate/pathology , Reflex, Pupillary/drug effects , Retinal Detachment/chemically induced , Retinal Perforations/chemically induced , Retrospective Studies , Tissue Adhesions/drug therapy , Visual Acuity/drug effects
2.
Vestn Oftalmol ; 118(4): 22-3, 2002.
Article in Russian | MEDLINE | ID: mdl-12371316

ABSTRACT

Morphological changes in case of failure of the lenticular ligamentous-capsular system are described. Histological changes in this complex led the authors to the conclusion that morphological substrata of the "traumatic" and "surgical" lenticular subluxation are similar and are characterized by coarse mechanical changes in the lens capsule, with the relatively intact structure of the ligamentous system at a considerable length. Subluxation of the lens resultant from oral drug therapy is characterized by pronounced changes in the lens capsule and in the short cinnous ligament fibers. Age-associated or involution subluxation is caused primarily by pathological changes in the lens capsule, which seems to experience high strain from the remaining zonular fibers.


Subject(s)
Lens Capsule, Crystalline/pathology , Lens Subluxation/pathology , Adrenal Cortex Hormones/adverse effects , Age Factors , Aged , Aged, 80 and over , Cataract Extraction , Eye Injuries/complications , Humans , Lens Implantation, Intraocular , Lens Subluxation/chemically induced , Lens Subluxation/etiology , Male , Time Factors
3.
Ophthalmic Surg ; 26(4): 343-5, 1995.
Article in English | MEDLINE | ID: mdl-8532288

ABSTRACT

There are 18 million persons blind from cataracts in Third-World countries and the number is doubling every 20 to 25 years. It is impossible to cure this many blind with present sophisticated surgical techniques. Enzymatic dislocation of the cataractous lens could be performed by nonmedical personnel and the patients given inexpensive mass-produced spectacles, which could solve this tremendous problem.


Subject(s)
Blindness/therapy , Cataract Extraction/methods , Cataract/complications , Lens Subluxation/chemically induced , Blindness/etiology , Chymotrypsin/administration & dosage , Developing Countries , Eyeglasses , Humans , Injections
4.
Ophthalmology ; 98(5): 636-8, 1991 May.
Article in English | MEDLINE | ID: mdl-2062495

ABSTRACT

The use of succinylcholine in patients with suspected or proven open globes is considered dangerous by some for fear of extruding the intra-ocular contents as a consequence of the co-contraction of the extraocular muscles it produces. To test this hypothesis, the authors devised an anterior and a posterior trauma model in the cat eye. Thirty events were studied using the anterior trauma model and eight with the posterior model. The only observable effect of succinylcholine administration was forward displacement of the lens and iris. No intraocular content was lost in any event. The authors believe this study supports the argument that, when indicated, succinylcholine may be considered in open globes.


Subject(s)
Eye Injuries/physiopathology , Succinylcholine/pharmacology , Animals , Cats , Disease Models, Animal , Eye Injuries/drug therapy , Intraocular Pressure/drug effects , Iris Diseases/chemically induced , Lens Subluxation/chemically induced , Muscle Contraction/drug effects , Oculomotor Muscles/drug effects
5.
Trans Ophthalmol Soc U K (1962) ; 104 ( Pt 5): 546-52, 1985.
Article in English | MEDLINE | ID: mdl-3876629

ABSTRACT

Complications in a group of 91 children with congenital and traumatic cataracts in whom intraocular lenses (IOL) have been implanted have been studied. The influence of viscoelastic substances (Healon) in the prevention and treatment of some of these complications, and as a causal factor in others, is presented. Ten different styles of lenses were implanted allowing a comparison of the relationship between the type of lens fixation and the complications observed.


Subject(s)
Lenses, Intraocular , Adolescent , Cataract/congenital , Cataract/etiology , Cataract Extraction , Child , Child, Preschool , Female , Humans , Hyaluronic Acid/adverse effects , Infant , Lens Subluxation/chemically induced , Male , Ocular Hypertension/chemically induced , Postoperative Complications , Uveitis/chemically induced , Vitrectomy , Vitreous Body
6.
Am J Vet Res ; 43(2): 207-16, 1982 Feb.
Article in English | MEDLINE | ID: mdl-6979957

ABSTRACT

Injection of 150, 500, or 750 U of alpha chymotrypsin into the posterior chamber of clinically normal Beagles resulted in changes in intraocular pressure and iridocyclitis. In the 6 eyes treated with 500 or 750 U, lens subluxation occurred in 4 eyes, retinal detachment in 1 eye, retinal degeneration in 1 eye, and optic nerve degeneration in 6 eyes. Scanning electron microscopic changes included dose-related zonulolysis and zonulary remnants within the aqueous humor outflow pathways. Ultrastructural changes by transmission microscopy of the optic nerve degeneration revealed loss of axoplasm and organelles and disruption of the myelin sheaths. Retinal and optic nerve changes may represent the direct toxic effects of alpha chymotrypsin and/or the indirect effects of increased intraocular pressure.


Subject(s)
Chymotrypsin/adverse effects , Dog Diseases/chemically induced , Eye Diseases/veterinary , Eye/drug effects , Animals , Dogs , Eye/pathology , Eye Diseases/chemically induced , Eye Diseases/pathology , Intraocular Pressure/drug effects , Lens Subluxation/chemically induced , Microscopy, Electron , Nerve Degeneration , Ocular Physiological Phenomena , Optic Nerve/pathology , Optic Nerve Diseases/chemically induced , Retinal Degeneration/chemically induced , Retinal Detachment/chemically induced , Uveitis, Anterior/chemically induced
SELECTION OF CITATIONS
SEARCH DETAIL
...